Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Osimertinib as First Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer: the Experience of the Hellenic Cooperative Oncology Group (HeCOG)

NCT05127382 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

NCT NCT05127382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05127382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Osimertinib as First Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer: the Experience of the Hellenic Cooperative Oncology Group (HeCOG)
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Observational
Overall status
Unknown status
Start date
February 1, 2020
Completion date
January 31, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer non-small cell stage iv